

1362 - Osiris Therapeutics Inc

General - Incorporation.....WI
 Employees9,387
 AuditorDeloitte & Touche LLP
 Stk Agt.....First Union Nat'l Bank
 Counsel.....NA
 DUNS No.....00-607-0445

Stock - Price on:12/24/2007\$64.13
 Stock Exchange.....NYSE
 Ticker Symbol.....OSK
 Outstanding Shares74,060,000
 E.P.S.....\$3.58
 Shareholders.....NA

Business: The groups principle activities include designing, manufacturing and marketing a range of specialty vehicles and vehicle bodies. The group operates through four segments namely access equipment, defense, fire and emergency, and commercial. The group operates from United States.

Primary SIC and add'l.: 5012 3713 3715 3531 3711

CIK No: 0000775158

Subsidiaries: 3841189 Canada, Inc., Bayside Underwriters Insurance Agency, Inc., Commercial Resource Services Company, Drive Insurance Holdings, Inc., Drive New Jersey Insurance Company, Drive Resource Services Company, Garden Sun Insurance Services, Inc., Greenberg Financial Insurance Services, Inc., Insurance Confirmation Services, Inc., Lakeside Insurance Agency, Inc., Midland Financial Group, Inc., Midland Risk Services, Inc., Mountain Laurel Assurance Company, National Continental Insurance Company, Pacific Motor Club 48 Subsidiaries included in the Index

Officers: John W. Randjelovic/CEO, Exec. VP - Fire, Emergency Group, Robert G. Bohn/Chmn., CEO, Michael J. Wuest/Exec. VP, Pres. - Mcneilus Companies, Inc, David M. Sagehorn/CFO, Exec. VP, Treasurer, Tom Cihowiak/New Product Information, Airport, Municipal, Arff, Michael S. Guzowski/VP - Information Technology, Matthew J. Zolnowski/Exec. VP, Chief Administration Officer, Charles L. Szews/COO, Pres., Thomas J. Polnaszek/Sr. VP - Finance, Donald H. Verhoff/Exec. VP - Technology, Thomas D. Fenner/Exec. VP, Pres. - Fire, Emergency Group, Michael K. Rohrkaste/VP - Human Resources, Joseph H. Kimmitt/Exec. VP - Government Operations, Industry Relations, John W. Stoddart/Exec. VP, Pres. - Defense Business, Scott L. Ney/Pres. - Oshkosh Capital (16 Officers included in Index)

Directors: Robert G. Bohn/Chmn., CEO, Robert A. Cornog/Dir., Richard G. Sim/Dir., William J. Andersen/Dir., Harvey Medvin/Dir., Frederick M. Franks/Dir., Kathleen J. Hempel/Dir., Richard M. Donnelly/Dir., Donald V. Fites/Dir., Peter J. Mosling/Dir., Timothy J. Roemer/Dir., Michael W. Grebe/Dir.

Owners: Kathleen J. Hempel, Bryan J. Blankfield, Charles L. Szews, Joseph H. Kimmitt, Insiders/3.98%, Robert A. Cornog, Richard M. Donnelly, T. Rowe Price Associates, Inc./9.64%, Harvey N. Medvin, Donald V. Fites, Frederick M. Franks, Matthew J. Zolnowski, Robert G. Bohn/1.35%, William J. Andersen, Richard G. Sim (18 Owners included in Index)

Financial Data: Fiscal Year End:09/30 Latest Annual Data: 9/30/2006

Year	Sales	Net Income
2006	\$3,427,388,000	\$205,529,000
2005	\$2,959,900,000	\$160,205,000
2004	\$2,262,305,000	\$112,806,000

Curr. Assets: \$2,194,900,000 **Curr. Liab.:** \$1,548,000,000 **P/E Ratio:** 24.57
Plant, Equip.: \$429,600,000 **Total Liab.:** \$5,002,400,000 **Indic. Yr. Divd.:** \$0.400
Total Assets: \$6,399,800,000 **Net Worth:** \$1,393,600,000 **Debt/Equity:** NA

OSI Pharmaceuticals

41 Pinelawn Rd., Melville, NY, 11747; **PH:** 1-631-962-2000; **Fax:** 1-631-752-3880;

http:// www.osip.com; **Email:** investor_info@osip.com

General - Incorporation.....DE
 Employees611
 AuditorKPMG LLP
 Stk Agt.....Bank of New York
 Counsel.....Saul Ewing LLP
 DUNS No.....10-901-4720

Stock - Price on:12/24/2007\$36.99
 Stock Exchange.....NDQ
 Ticker Symbol.....OSIP
 Outstanding Shares57,660,000
 E.P.S.....-\$3.79
 Shareholders.....NA

Business: The group's principal activities are to discover, develop and market oncology products. The group's advanced drug tarceva(tm), an anti-cancer agent is undergoing phase iii clinical trials for non-small lung cancer and pancreatic cancer. Tarceva(tm) is being developed in a global alliance with genentech inc and roche holdings inc. In addition, it has five other drug candidates in early stages of clinical development, out of which three are next generation cytotoxic chemotherapy agents and three are gene-targeted therapies currently being developed by pfizer inc. The products of the group include novantrone(R) and gelclair(R). On, 12-Jun-2003, the group acquired cell pathways inc.

Primary SIC and add'l.: 8731 2834

CIK No: 0000729922

Subsidiaries: OSI Eyetech, Inc., OSI Pharmaceuticals (UK) Limited, Prosidion Limited

Officers: Colin Goddard/Dir., CEO/\$1,905,478.00, Robert Simon/Exec. VP - Pharmaceutical Development, Manufacturing, Gabriel Leung/Pres. - OSI Oncology/\$1,528,831.00, Anker Lundemose/Exec. VP, Pres. - OSI Prosidion/\$1,301,307.00, Barbara A. Wood/VP, General Counsel, Sec., Michael G. Atieh/CFO, Exec. VP/\$2,066,244.00, Paul G. Chaney/Exec. VP, Pres. - OSI Eyetech/\$1,636,464.00, Neil Gibson/VP, Chief Scientific Officer, Linda E. Amper/VP - Business Administration, Human Resources

Directors: Colin Goddard/Dir., CEO, Robert A. Ingram/Chmn., Herbert Michael Pinedo/Dir., Daryl K. Granner/Dir., Viren Mehta/Dir., John P. White/Dir., Walter M. Lovenberg/Dir., Katharine B. Stevenson/Dir., Morgan G. Browne/Dir., Santo J. Costa/62/Dir., Joseph Klein/Dir., David W. Niemiec/Dir., Kenneth B. Lee/Dir.

Owners: Santo J. Costa, Colin Goddard, Insiders/3.20%, John P. White, OrbiMed Advisors LLC/5.70%, Daryl K. Granner, Paul G. Chaney, Gabriel Leung, T. Rowe Price Associates Inc./6.60%, Katharine B. Stevenson, Morgan G. Browne, Robert A. Ingram, Westfield Capital Management Co./8.00%, Viren Mehta, Walter M. Lovenberg (23 Owners included in Index)

Financial Data: Fiscal Year End:12/31 Latest Annual Data: 12/31/2006

Year	Sales	Net Income
2006	\$375,696,000	-\$582,184,000
2005	\$174,194,000	-\$157,123,000
2004	\$42,800,000	-\$260,371,000

Curr. Assets: \$275,445,000 **Curr. Liab.:** \$47,222,000
Plant, Equip.: \$35,356,000 **Total Liab.:** \$233,796,000 **Indic. Yr. Divd.:** NA
Total Assets: \$388,029,000 **Net Worth:** \$154,233,000 **Debt/Equity:** NA

OSI Restaurant Partners Inc

Formerly: Outback Steakhouse Inc

2202 N W Shore Blvd., Ste. 500, Tampa, FL, 33607; **PH:** 1-813-282-1225; **http://** www.outback.com

General - IncorporationDE
 Employees95,000
 AuditorPricewaterhouseCoopers LLP
 Stk Agt.....Bank of New York
 Counsel.....Baker & Hostetler
 DUNS No.....18-583-8968

Stock - Price on:12/24/2007NA
 Stock Exchange.....NA
 Ticker Symbol.....NA
 Outstanding SharesNA
 E.P.S.....NA
 Shareholders.....NA

Business: The group's principal activity is to develop and operate casual dining restaurants. It offers consumers of different demographic backgrounds an array of dining alternatives suited for differing needs. The restaurants serve dinner only and feature a limited menu of seasoned steaks, prime rib, chops, barbecued ribs, chicken, fish and pasta. The group has seven restaurant concepts, over 1000 system-wide restaurants. The operations are conducted through company-owned stores in 50 states and in 21 countries internationally. Outback steakhouse, carrabba's Italian grill, fleming's prime steakhouse and wine bar, roy's, cheeseburger in paradise, bonefish grill, lee roy selmon's and paul lee's Chinese kitchen service marks and 'bloomin' onion' are the trademarks under which the group markets its restaurants. On 01-Jul-2003, the group acquired 14 outback steakhouse restaurants operating in Alabama and Florida.

Primary SIC and add'l.: 6794 5812

CIK No: 0000874691

Subsidiaries: Bonefish Grill, Inc., Boomerang Air, Inc., Carrabba's Italian Grill, Inc., OS Asset, Inc., OS Capital, Inc., OS Cathy, Inc., OS Investments, Inc., OS Management, Inc., OS Marketing Services, Inc., OS Mortgage Holdings, Inc., OS Pacific, Inc., OS Prime, Inc., OS Realty, Inc., OS Restaurant Services, Inc., f.k.a. Outback Employee Services, Inc., OS Southern, Inc. 25 Subsidiaries included in the Index

Officers: William A. Allen/48/Dir., CEO, Dirk A. Montgomery/44/CFO, Joseph J. Kadow/51/Chief Officer - Legal, Corporate Affairs, Exec. VP, Paul E. Avery/48/COO

Directors: William A. Allen/48/Dir., CEO, Chris T. Sullivan/60/Chmn., Co - Founder, Robert D. Basham/60/Co - Founder, Vice Chmn., Debbi Fields/51/Dir., Toby S. Wilt/63/Dir., Thomas A. James/65/Dir., John A. Brabson/67/Dir., Tommy Franks/62/Dir., Lee Roy Selmon/53/Dir., William R. Carey/60/Dir.

Owners: Debbi Fields, Paul E. Avery, Capital Research and Management Company/9.10%, Toby S. Wilt, Dirk A. Montgomery, Joseph J. Kadow, OSI Investors as a group/11.90%, John A. Brabson, Steven T. Shlemon, William A. Allen, Thomas A. James, Chris T. Sullivan/3.20%, Insiders/11.40%, FMR Corp./8.10%, Tommy Franks (20 Owners included in Index)

OSI Systems Inc

12525 ChaDr.on Ave., Hawthorne, CA, 90250; **PH:** 1-310-978-0516; **Fax:** 1-310-644-7213;

http:// www.osi-systems.com

General - IncorporationCA
 Employees2,580
 AuditorDeloitte & Touche LLP
 Stk Agt.....U.S. Stock Transfer Corp
 Counsel.....Richman Et Al
 DUNS No.....94-837-1356

Stock - Price on:12/24/2007\$27.92
 Stock Exchange.....NDQ
 Ticker Symbol.....OSIS
 Outstanding Shares16,980,000
 E.P.S.....-\$0.88
 Shareholders.....NA

Business: The group's principal activity is to manufacture and sell optoelectronic devices and subsystems and medical imaging systems. The group designs and manufactures optoelectronic devices and value-added subsystems for original equipment manufacturers. The group utilizes the optoelectronic technology and designs to manufacture security and inspection products, sold under the brand names: rapiscan, secure and metor. In the medical field, the group manufactures and sells bone densitometers and saturation of arterial hemoglobin, under the trade names digital dolphin(tm) and dolphin 2000(TM). The group markets its products across North America, Europe and Asia. During 2004, the group acquired all assets of schwartz electro-optics, inc & advanced research and applications corporation. On 19-Mar-2004, the group acquired space labs medical.

Primary SIC and add'l.: 3826 3674 3841 3827 7382

CIK No: 0001039065

Subsidiaries: Advanced Micro Electronics AS, Blease Medical Equipment Limited, Blease Medical Holdings Limited, Blease Medical Services Limited, Corrigan Canada, Ltd., CXR Limited, Del Mar Reynolds GmbH, Del Mar Reynolds Medical Limited, Del Mar Reynolds Medical, Inc., Dolphin Medical Pte Ltd., Dolphin Medical, Inc., Ferson Technologies, Inc., Hertford Cardiology Limited, Hertford Medical International Limited, Metorex Security Products, Inc. 50 Subsidiaries included in the Index

Officers: Deepak Chopra/Chmn., CEO, Pres., Ajay Mehra/Dir., Exec. VP, Anuj Wadhawan/CFO, Treasurer, Alan Edrick/CFO, Exec. VP, Victor Sze/Exec. VP, Company Sec., General Counsel, Jeremy Norton/Dir. - Investor Relations, Manoocher Mansouri/Pres.

Directors: Deepak Chopra/Chmn., CEO, Pres., Steve Good/Dir., Meyer Luskin/Dir., Chand R. Viswanathan/Dir., Leslie E. Bider/58/Dir.

Owners: Steven C. Good/0.30%, Manoocher Mansouri/0.20%, Alan Edrick/0.10%, Insiders/10.60%, Wells Fargo & Company/13.00%, Leslie E. Bider, Deepak Chopra/7.80%, Chand R. Viswanathan/0.10%, Ajay Mehra/1.20%, Victor S. Sze/0.20%, Dimensional Fund Advisors, Inc./8.30%, Anuj Wadhawan/0.40%, Wellington Management Company, LLP/7.70%, Turner Investment Partners, Inc./5.20%, Meyer Luskin/0.30%

Financial Data: Fiscal Year End:06/30 Latest Annual Data: 06/30/2007

Year	Sales	Net Income
2007	\$532,284,000	-\$18,758,000
2006	\$452,686,000	-\$2,358,000
2005	\$385,041,000	-\$2,395,000

Curr. Assets: \$283,724,000 **Curr. Liab.:** \$121,568,000
Plant, Equip.: \$42,521,000 **Total Liab.:** \$144,820,000 **Indic. Yr. Divd.:** NA
Total Assets: \$403,498,000 **Net Worth:** \$248,947,000 **Debt/Equity:** 0.1130

Osiris Therapeutics Inc

7015 Albert Einstein Dr., Columbia, MD, 21046; **PH:** 1-443-545-1800; **Fax:** 1-443-545-1701;

http:// www.osiristx.com; **Email:** osiris@osiris.com

General - IncorporationDE
 Employees73
 AuditorKPMG LLP
 Stk Agt.....Stock Transfer & Trust Co
 Counsel.....NA
 DUNS No.....NA

Stock - Price on:12/24/2007\$12.96
 Stock Exchange.....NDQ
 Ticker Symbol.....OSIR
 Outstanding Shares27,470,000
 E.P.S.....-\$2.42
 Shareholders.....NA

Business: The groups principal activities include developing and marketing medical services. The products of the group include Osteocel, Prochymal, Chondrogen and Provacel. The group operates from the United States.

Primary SIC and add'l.: 2836 8731